                         SEQUENCE LISTING

<110>  Universitaet Wien
 
<120>  Silaffin silica particle adjuvant

<130>  P70852PC

<160>  34    

<170>  PatentIn version 3.5

<210>  1
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide based on the silaffin repetitive unit

<400>  1

Ser Ser Lys Lys Ser Gly Ser Tyr Ser Gly Ser Lys Gly Ser Lys Arg 
1               5                   10                  15      


Arg Ile Leu 
            


<210>  2
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide I

<400>  2

Lys Arg Arg Ile Leu 
1               5   


<210>  3
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide generic sequence


<220>
<221>  Xaa
<222>  (4)..(4)
<223>  peptide bond or Ile moiety

<400>  3

Arg Arg Ile Xaa Leu 
1               5   


<210>  4
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide II

<400>  4

Arg Arg Ile Leu 
1               


<210>  5
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide III

<400>  5

Arg Arg Ile Ile Leu 
1               5   


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide dimer I

<400>  6

Arg Arg Ile Leu Lys Arg Arg Ile Leu 
1               5                   


<210>  7
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide dimer II


<220>
<221>  Xaa
<222>  (5)..(5)
<223>  Lys conjugated to the preceding Leu via its epsilon amino group

<400>  7

Arg Arg Ile Leu Xaa Arg Arg Ile Leu 
1               5                   


<210>  8
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide dimer III


<220>
<221>  Xaa
<222>  (6)..(6)
<223>  Lys conjugated to the preceding Leu via its epsilon amino group

<400>  8

Arg Arg Ile Ile Leu Xaa Arg Arg Ile Leu 
1               5                   10  


<210>  9
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide dimer IV

<400>  9

Arg Arg Ile Leu Lys Arg Arg Ile Ile Leu 
1               5                   10  


<210>  10
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide dimer V

<400>  10

Arg Arg Ile Ile Leu Lys Arg Arg Ile Leu 
1               5                   10  


<210>  11
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide dimer VI

<400>  11

Arg Arg Ile Ile Leu Lys Arg Arg Ile Ile Leu 
1               5                   10      


<210>  12
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide dimer VII


<220>
<221>  Xaa
<222>  (5)..(5)
<223>  Lys conjugated to the preceding Leu via its epsilon amino group

<400>  12

Arg Arg Ile Leu Xaa Arg Arg Ile Ile Leu 
1               5                   10  


<210>  13
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide dimer VIII


<220>
<221>  Xaa
<222>  (6)..(6)
<223>  Lys conjugated to the preceding Leu via its epsilon amino group

<400>  13

Arg Arg Ile Ile Leu Xaa Arg Arg Ile Ile Leu 
1               5                   10      


<210>  14
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  alternative structure for rod formation

<400>  14

Ile Ile Ile Lys 
1               


<210>  15
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  divalent conjugate generic structure


<220>
<221>  Xaa
<222>  (4)..(4)
<223>  peptide bond or Ile

<220>
<221>  Xaa
<222>  (6)..(6)
<223>  any amino acid

<220>
<221>  Xaa
<222>  (10)..(10)
<223>  peptide bond or Ile

<400>  15

Arg Arg Ile Xaa Leu Xaa Arg Arg Ile Xaa Leu 
1               5                   10      


<210>  16
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide dimer IX

<400>  16

Leu Ile Arg Arg Lys Arg Arg Ile Leu 
1               5                   


<210>  17
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin dimer X


<220>
<221>  Xaa
<222>  (5)..(5)
<223>  Lys conjugated to the preceding Leu via its epsilon amino group

<400>  17

Leu Ile Arg Arg Xaa Arg Arg Ile Leu 
1               5                   


<210>  18
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide XIV

<400>  18

Arg Arg Ile Leu Lys Leu Ile Ile Arg Arg 
1               5                   10  


<210>  19
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  reverse motif

<400>  19

Leu Ile Arg Arg 
1               


<210>  20
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  divalent generic structure II


<220>
<221>  Xaa
<222>  (2)..(2)
<223>  peptide bond or Ile

<220>
<221>  Xaa
<222>  (6)..(6)
<223>  any amino acid residue

<220>
<221>  Xaa
<222>  (10)..(10)
<223>  peptide bond or Ile

<400>  20

Leu Xaa Ile Arg Arg Xaa Arg Arg Ile Xaa Leu 
1               5                   10      


<210>  21
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  alternative reverse motif

<400>  21

Leu Ile Ile Arg Arg 
1               5   


<210>  22
<211>  265
<212>  PRT
<213>  Cylindrotheca fusiformis

<400>  22

Met Lys Leu Thr Ala Ile Phe Pro Leu Leu Phe Thr Ala Val Gly Tyr 
1               5                   10                  15      


Cys Ala Ala Gln Ser Ile Ala Asp Leu Ala Ala Ala Asn Leu Ser Thr 
            20                  25                  30          


Glu Asp Ser Lys Ser Ala Gln Leu Ile Ser Ala Asp Ser Ser Asp Asp 
        35                  40                  45              


Ala Ser Asp Ser Ser Val Glu Ser Val Asp Ala Ala Ser Ser Asp Val 
    50                  55                  60                  


Ser Gly Ser Ser Val Glu Ser Val Asp Val Ser Gly Ser Ser Leu Glu 
65                  70                  75                  80  


Ser Val Asp Val Ser Gly Ser Ser Leu Glu Ser Val Asp Asp Ser Ser 
                85                  90                  95      


Glu Asp Ser Glu Glu Glu Glu Leu Arg Ile Leu Ser Ser Lys Lys Ser 
            100                 105                 110         


Gly Ser Tyr Tyr Ser Tyr Gly Thr Lys Lys Ser Gly Ser Tyr Ser Gly 
        115                 120                 125             


Tyr Ser Thr Lys Lys Ser Ala Ser Arg Arg Ile Leu Ser Ser Lys Lys 
    130                 135                 140                 


Ser Gly Ser Tyr Ser Gly Tyr Ser Thr Lys Lys Ser Gly Ser Arg Arg 
145                 150                 155                 160 


Ile Leu Ser Ser Lys Lys Ser Gly Ser Tyr Ser Gly Ser Lys Gly Ser 
                165                 170                 175     


Lys Arg Arg Ile Leu Ser Ser Lys Lys Ser Gly Ser Tyr Ser Gly Ser 
            180                 185                 190         


Lys Gly Ser Lys Arg Arg Asn Leu Ser Ser Lys Lys Ser Gly Ser Tyr 
        195                 200                 205             


Ser Gly Ser Lys Gly Ser Lys Arg Arg Ile Leu Ser Ser Lys Lys Ser 
    210                 215                 220                 


Gly Ser Tyr Ser Gly Ser Lys Gly Ser Lys Arg Arg Asn Leu Ser Ser 
225                 230                 235                 240 


Lys Lys Ser Gly Ser Tyr Ser Gly Ser Lys Gly Ser Lys Arg Arg Ile 
                245                 250                 255     


Leu Ser Gly Gly Leu Arg Gly Ser Met 
            260                 265 


<210>  23
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  general forward sequence motif for silica precipitation


<220>
<221>  Xaa
<222>  (3)..(3)
<223>  any hydrophobic amino acid moiety

<220>
<221>  Xaa
<222>  (4)..(4)
<223>  peptide bond or any hydrophobic amino acid moiety

<400>  23

Arg Arg Xaa Xaa Leu 
1               5   


<210>  24
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  general reverse sequence motif for silica precipitation


<220>
<221>  Xaa
<222>  (2)..(2)
<223>  any hydrophobic amino acid moiety

<220>
<221>  Xaa
<222>  (3)..(3)
<223>  peptide bond or any hydrophobic amino acid moiety

<400>  24

Leu Xaa Xaa Arg Arg 
1               5   


<210>  25
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  general divalent peptide I


<220>
<221>  Xaa
<222>  (3)..(3)
<223>  any hydrophobic amino acid moiety

<220>
<221>  Xaa
<222>  (4)..(4)
<223>  peptide bond or any hydrophobic amino acid moiety

<220>
<221>  Xaa
<222>  (6)..(6)
<223>  any peptide moiety of not more than five consecutive amino acid 
       moieties

<220>
<221>  Xaa
<222>  (9)..(9)
<223>  any hydrophobic amino acid moiety

<220>
<221>  Xaa
<222>  (10)..(10)
<223>  ppetide bond or any hydrophobic amino acid moiety

<400>  25

Arg Arg Xaa Xaa Leu Xaa Arg Arg Xaa Xaa Leu 
1               5                   10      


<210>  26
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  general divalent peptide II


<220>
<221>  Xaa
<222>  (2)..(2)
<223>  any hydrophobic amino acid moiety

<220>
<221>  Xaa
<222>  (3)..(3)
<223>  peptide bond or any hydrophobic amino acid moiety

<220>
<221>  Xaa
<222>  (6)..(6)
<223>  any peptide moiety of not more than five consecutive amino acid 
       moieties

<220>
<221>  Xaa
<222>  (9)..(9)
<223>  any hydrophobic amino acid moiety

<220>
<221>  Xaa
<222>  (10)..(10)
<223>  ppetide bond or any hydrophobic amino acid moiety

<400>  26

Leu Xaa Xaa Arg Arg Xaa Arg Arg Xaa Xaa Leu 
1               5                   10      


<210>  27
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  branched sequence


<220>
<221>  Xaa
<222>  (5)..(5)
<223>  Lys bearing a sequence of four or five consecutive amino acid 
       residues conjugated to the epsilon amino group of the Lys

<400>  27

Leu Ile Arg Arg Xaa Arg Arg Ile Leu 
1               5                   


<210>  28
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  general divalent peptide III


<220>
<221>  Xaa
<222>  (3)..(3)
<223>  any hydrophobic amino acid moiety

<220>
<221>  Xaa
<222>  (4)..(4)
<223>  peptide bond or any hydrophobic amino acid moiety

<220>
<221>  Xaa
<222>  (6)..(6)
<223>  any peptide moiety of not more than five consecutive amino acid 
       moieties

<220>
<221>  Xaa
<222>  (8)..(8)
<223>  any hydrophobic amino acid moiety

<220>
<221>  Xaa
<222>  (9)..(9)
<223>  peptide bond or any hydrophobic amino acid moiety

<400>  28

Arg Arg Xaa Xaa Leu Xaa Leu Xaa Xaa Arg Arg 
1               5                   10      


<210>  29
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide XV


<220>
<221>  Xaa
<222>  (6)..(6)
<223>  Lys conjugated to the preceding Leu via its epsilon amino group

<400>  29

Arg Arg Ile Leu Leu Xaa Arg Arg Ile Leu 
1               5                   10  


<210>  30
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide XVI


<220>
<221>  Xaa
<222>  (6)..(6)
<223>  Lys conjugated to the preceding Leu via its epsilon amino group

<400>  30

Arg Arg Ile Ile Leu Xaa Arg Arg Leu Leu 
1               5                   10  


<210>  31
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin PEG conjugate


<220>
<221>  Xaa
<222>  (5)..(5)
<223>  polyethylene glycol  (PEG)3-conjugated to the preceding Leu and 
       tehsubsequent Arg

<400>  31

Arg Arg Ile Leu Xaa Arg Arg Ile Leu 
1               5                   


<210>  32
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  silaffin peptide

<400>  32

Ser Ile Ile Asn Phe Glu Lys Leu Cys Ser Ser Lys Lys Ser Gly Ser 
1               5                   10                  15      


Tyr Ser Gly Ser Lys Gly Ser Lys Arg Arg Ile Leu 
            20                  25              


<210>  33
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide XVII

<400>  33

Arg Arg Ile Leu Leu 
1               5   


<210>  34
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  truncated silaffin peptide XVIII

<400>  34

Arg Arg Leu Leu 
1               


